Contact information
michael.desborough@linacre.ox.ac.uk
michael.desborough@ouh.nhs.uk
Department of Clinical Haematology, Churchill Hospital, Oxford, OX3 9DU
He/Him
Colleges
Michael Desborough
BMedSci(Hons), MB ChB, FRCP, FRCPath, DPhil
Consultant Haematologist & Associate Professor of Haematology
The overarching aim of the research conducted by my group is to develop and trial new treatments for platelet disorders and finding alternatives to platelet transfusion.
- This includes trials of reversing antiplatelet drugs in intracerebral haemorrhage
- Optimising treatment of fetal and neonatal alloimmune thrombocytopenia (FNAIT)
- Clinical trials in transfusion medicine and immunohaematology [thrombotic thrombocytopenic purpura (TTP), immune thrombocytopenia (ITP), warm autoimmune haemolytic anaemia (wAIHA), cold agglutinin disease (CAD)]
- Developing the evidence base for platelet transfusion and alternatives to transfusion
Key publications
Desmopressin for patients with spontaneous intracerebral haemorrhage taking antiplatelet drugs (DASH): a UK-based, phase 2, randomised, placebo-controlled, multicentre feasibility trial
Journal article
Desborough MJR. et al, (2023), The Lancet Neurology, 22, 557 - 567
ORCID
0000-0002-1951-5616